Real-world Study of Sunvozertinib Treatment in Locally Advanced or Metastatic EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
Latest Information Update: 27 Jan 2025
Price :
$35 *
At a glance
- Drugs Sunvozertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Jan 2025 New trial record